Insmed (INSM) Misses Q4 EPS by 1c, Revenues Beat; Provides FY20 Sales Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. LITE
4. AAPL
5. ABBV
6. MRVL
7. CL
8. LYB
9. TFII
10. SPY

Go back to Insmed (INSM) Misses Q4 EPS by 1c, Revenues Beat; Provides FY20 Sales Guidance

Insmed Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

February 25, 2020 7:30 AM EST

BRIDGEWATER, N.J., Feb. 25, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided a business update.  

"2019 was a transformative year for Insmed as we evolved into a commercial-stage organization and advanced our global infrastructure. I am incredibly proud of our team's performance in the first full year of the ARIKAYCE U.S. launch, and we look forward... More